Press Release
Neuralia TMS Broadens Access to Non-Invasive TMS Treatment for Depression
Australia, 27th Jan 2026 – Neuralia TMS, a respected provider of non-invasive neuromodulation therapies, has announced an expansion of access to Transcranial Magnetic Stimulation treatment for individuals living with depression, reflecting continued developments in evidence-based mental health care and increasing demand for non-pharmacological treatment options. The expanded availability is intended to support patients seeking additional clinical pathways under medical supervision.
Transcranial Magnetic Stimulation, commonly known as TMS, is a non-invasive procedure that uses targeted magnetic pulses to stimulate specific areas of the brain associated with mood regulation. The treatment does not involve medication or surgery and is delivered in an outpatient setting. Over the past two decades, TMS has been studied extensively and incorporated into treatment guidelines in several countries for individuals with major depressive disorder, particularly where symptoms have persisted despite standard treatment approaches.
The expanded access initiative follows increased clinical interest in treatment pathways that complement existing mental health care models. Depression remains a significant public health concern, with many individuals experiencing ongoing symptoms that affect daily functioning, work participation, and quality of life. In response, mental health services continue to explore a broader range of evidence-based interventions that can be delivered safely and effectively under medical supervision.
Dr Shanek Wick, Medical Director at Neuralia TMS, said the expansion reflects a focus on improving availability of established neuromodulation therapies for appropriate patients. “Transcranial Magnetic Stimulation is a non-invasive treatment option that has been supported by a growing body of clinical research for the management of depression,” Dr Wick said. “Broadening access allows more individuals to be assessed for suitability within a structured medical framework.”
Neuralia TMS provides TMS therapy as part of a comprehensive clinical assessment process, ensuring that treatment plans are informed by individual health history and current clinical needs. Sessions are typically delivered over a course of scheduled appointments, allowing patients to continue with usual daily activities during treatment. Reported side effects are generally mild and temporary, most commonly including scalp discomfort or headache during early sessions.
In addition to depression-focused care, Neuralia TMS offers neuromodulation services for a range of neurological and psychiatric conditions, including anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, chronic pain, and Parkinson’s disease. The clinic also provides transcranial Direct Current Stimulation, an at-home neuromodulation therapy delivered under clinical guidance, and pharmacogenetic testing to support personalised treatment planning based on genetic factors. These services are integrated into broader care considerations rather than positioned as replacements for established mental health treatments.
The expansion of TMS access aligns with wider trends in mental health care that emphasise individualised treatment planning and multidisciplinary approaches. Clinicians increasingly recognise that effective management of depression often involves combining multiple evidence-based strategies, including psychological therapies, medication, and non-invasive interventions. Neuromodulation therapies are being considered as part of this broader continuum of care.
Health sector observers note that non-invasive brain stimulation continues to attract attention as research into brain function and mental health advances. Ongoing clinical studies are exploring how treatment protocols may be refined and how outcomes can be better predicted across different patient groups. Within this context, careful clinical oversight and adherence to established standards remain central to responsible implementation.
Dr Wick said continued evaluation and clinical development will remain important as the field evolves. “Future directions in neuromodulation are expected to involve more precise targeting, improved individualisation of treatment protocols, and closer integration with other mental health services,” Dr Wick said. “Ongoing research and clinical review will play an important role in guiding how these therapies are applied over time.”
Neuralia TMS stated that all patients undergo a comprehensive medical assessment to determine whether TMS is clinically appropriate. The clinic operates in accordance with established medical and professional standards, with an emphasis on informed decision-making and patient safety.
The announcement comes amid continued public discussion about access to timely and evidence-based mental health care. By expanding access to non-invasive TMS treatment for depression, Neuralia TMS aims to contribute to the availability of additional clinical options for individuals and referring practitioners seeking alternatives within a medically supervised setting.
For further information regarding the expanded access to TMS treatment for depression, media enquiries may be directed to Neuralia TMS. The clinic can be contacted by phone on 08 6230 3996 or via email at info@neuralia.com.au.
Media Contact
Organization: Neuralia TMS
Contact Person: Dr Shanek Wick
Website: https://www.neuraliatms.com.au/
Email: Send Email
Contact Number: +61862303996
Country:Australia
Release id:40609
Disclaimer: This announcement is provided for general informational purposes only and does not constitute medical advice. Transcranial Magnetic Stimulation suitability and outcomes vary by individual and should be determined through assessment by a qualified medical professional.
The post Neuralia TMS Broadens Access to Non-Invasive TMS Treatment for Depression appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CMS(867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals.
About CMS-D008
CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases.
Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity
Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles.
CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution
CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options.
The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
- Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564.
- World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23
- Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z
- Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
United States, 5th Mar 2026 – Oberheiden P.C. is pleased to announce that the firm’s asset protection attorneys are now offering Nevada asset protection trusts to clients nationwide. Nevada asset protection trusts are unique among domestic asset protection trusts (DAPTs) for their flexibility, and they can be powerful tools for insulating high-net-worth individuals’ assets from creditor claims both in and out of court.
According to the firm’s founding attorney, Dr. Nick Oberheiden, “While many high-net-worth individuals are familiar with the benefits afforded by offshore asset protection trusts, far fewer are familiar with the domestic options that are available. The Nevada asset protection trust can be a particularly good option for individuals who want to protect their assets within the United States while also taking advantage of the estate planning, tax planning, and other benefits that domestic trusts can afford.”
Dr. Oberheiden says that forming Nevada asset protection trust can be a particularly good option for several reasons. For example, while a Nevada asset protection trust is a type of irrevocable trust, a grantor (the individual who forms a trust) still has the ability to modify how they hold their assets over time. This distinguishes Nevada law from the laws of many other states. Nevada also has a shorter statute of limitations for creditor claims than most other states (two years in most cases), and Nevada law does not recognize any exception creditors.
“These factors, combined with the relative ease of forming a Nevada domestic asset protection trust, make using a Nevada DAPT a desirable option in a wide range of circumstances—including circumstances in which high-net-worth individuals might otherwise be looking at transferring assets into an offshore trust established in the Cook Islands or another foreign jurisdiction.” Dr. Oberheiden continues, “If you are interested in learning about your options for protecting your wealth from both known and unknown creditors, it will be worth talking to an attorney about whether a Nevada DAPT is a good option for your individual circumstances.”
While forming a Nevada DAPT involves leveraging the benefits afforded under the state’s trust laws, Dr. Oberheiden emphasizes that this is not solely an option for Nevada residents. “When the Nevada legislature adopted the state’s asset protection trust laws, it specifically opened up the possibility of forming a Nevada DAPT to individuals residing across the country. Although there are certain statutory requirements that make it important to work with a Nevada trust company, individuals nationwide can form statutory trusts in Nevada for asset protection purposes.”
Dr. Oberheiden is also quick to emphasize that while forming a Nevada DAPT is a desirable option in many cases, it is important for all high-net-worth individuals to make informed decisions about their asset protection needs based on their individual circumstances. “While forming a Nevada DAPT to protect real property and other assets will make sense for many individuals, it is important to consider the other options that are available as well. A few states offer self-settled spendthrift trust options that will meet individuals’ needs in some cases; and, in other cases, forming an offshore asset protection trust may be necessary to protect assets located around the world.”
“Additionally,” he continues, “limited liability companies and other vehicles can be used for asset protection as well. Purchasing liability insurance can be a cost-effective means of limiting high-net-worth individuals’ personal liability exposure as well. Ultimately, while we are now offering Nevada asset protection trusts, we are still focused on ensuring that we provide each of our clients with a custom-tailored solution focused on their specific risks and needs.”
Dr. Oberheiden says that high-net-worth individuals who are interested in learning about the options for safeguarding their assets in the U.S. and abroad are encouraged to contact the firm for a complimentary initial consultation. “We have a team of highly skilled asset protection attorneys who are committed to helping our clients protect their assets not only in the short term, but also for future generations.” He continues, “If you have questions, one of our attorneys will be more than happy to schedule a call to begin talking through your options in strict confidence.”
Nick Oberheiden, Founding Attorney, 888-680-1745 (Office)
Attorney Advertising – Oberheiden, P.C., is an asset protection law firm headquartered in Houston, TX with a nationwide network of senior attorneys and consultants. The firm’s asset protection attorneys are available to assist clients with Nevada asset protection trusts and other asset protection strategies throughout the United States. The firm’s addresses and contact information can be found at www.federal-lawyer.com/our-locations.
Media Contact
Organization: Oberheiden, P.C.
Contact Person: Nick Oberheiden, Founding Attorney
Website: https://federal-lawyer.com/asset-protection/
Email: Send Email
Contact Number: +18886801745
Country:United States
Release id:42208
Disclaimer: This press release is provided for general informational purposes only and does not constitute legal, financial, or professional advice.
The post Oberheiden P.C. Now Offering Nevada Asset Protection Trusts appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Dubai, UAE, 5th March 2026, ZEX PR WIRE, SPL VPN has announced an architectural transition to an AI-driven routing engine, effectively automating global server selection for its two million users. The shift replaces traditional manual configurations with a proprietary protocol designed to eliminate connection guesswork and latency issues.
As digital privacy requirements evolve, SPL VPN is prioritizing usability through a system that analyzes network congestion, ISP throttling, and packet loss in real-time. This “zero-touch” approach automatically builds optimized routes for specific traffic types, such as streaming or secure browsing, without user intervention.
The update features predictive reconnection technology, allowing the infrastructure to anticipate node failures and switch paths before a connection drop occurs. This technical advancement is reflected in the platform’s new adaptive interface, which simplifies the experience for over 500,000 daily active users by removing legacy server lists.
“The future of connectivity is a seamless layer that functions before the user identifies a need for it,” stated the Head of Product at SPL. “After eight years of development, we are moving beyond the industry’s traditional ‘server-count race’ toward a model of delivery intelligence.”
Established in 2018, SPL VPN has consistently combined encryption standards with emerging AI research. This latest expansion strengthens the company’s position as a utility-focused provider for the modern web, offering a faster and more intuitive framework for global digital security.
About SPL VPN
SPL VPN is a global provider of digital privacy solutions. Established in 2018 in Singapore, the company utilizes AI-driven routing and military-grade encryption to provide secure, high-performance internet access for over 2 million users worldwide.
Website: https://splvpn.com/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
CMS(867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Oberheiden P.C. Now Offering Nevada Asset Protection Trusts
SPL VPN Announces AI-Driven Architectural Shift to Replace Manual Server Routing
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release6 days ago
SPL VPN Leverages AI to Eliminate Manual Server Selection; Surpasses 2 Million Downloads in Connectivity Pivot
-
Press Release1 week ago
Lake Worth Beach Bail Bonds Services Expanded with County-Focused Release Strategy
-
Press Release5 days ago
Sports Mouthguards for Muskegon Youth – What Families Should Know
-
Press Release1 week ago
Cabinet Paint Color Trends Shape Tampa Bay Kitchens in 2026
-
Press Release1 week ago
4D Heng Leverages AI Technology to Enhance Integrity and Speed of Southeast Asian Lottery Data
-
Press Release6 days ago
ZentoraReach Leads Client Acquisition & Revenue Growth for Contractors
-
Press Release4 days ago
LTR Taxis Redefines Reliable Private Travel Across the UK with Customer-First Airport & Long-Distance Taxi Services
-
Press Release6 days ago
Faith, Family, and Leadership: How Brent Byng Grounds His Approach to Success